MedTrace Logo

Exercise Prescription in Cardiac Rehabilitation Mediated by Autonomic Function

NCT07288840 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2025-12-17

No results posted yet for this study

Summary

Cardiac rehabilitation (CR) is an essential secondary prevention component in the treatment of cardiovascular diseases and one of the most cost- effective clinical interventions. Exercise training (ET) in CR programs (CRP) has unequivocal benefits in the reduction of cardiovascular adverse events, by decreasing the overactivated sympathetic tone. This ET added value can be measured by variables that express autonomic control using indirect (standard) or direct (experimental) methodologies. Direct autonomic assessment (ex. Microneurography) is accurate but unusable in daily practice, whereas standard indirect autonomic assessment using clinical parameters is imprecise, resulting in underprescription to safeguard patient safety, with less benefit to the patients. In this project, we aim to apply Machine Learning models to a set of indirect and direct variables, to make a multivariate correlation analysis and so define a normalization factor for exercise prescription.

Conditions

  • Cardiac Rehabilitation
  • Exercise Therapy
  • Autonomic Nervous System Imbalance
  • Treatment Outcomes

Sponsors & Collaborators

  • Universidade do Minho - ICVS

    collaborator UNKNOWN

  • Hospital Santo André - Centro Hospitalar de Leiria

    collaborator UNKNOWN

  • Fundação para a Ciência e a Tecnologia (FCT)

    collaborator UNKNOWN

  • Instituto Politécnico de Leiria

    lead OTHER

Principal Investigators

  • Vitor Hugo Eira Pereira, MD, PhD · ICVS - Life and Health Sciences Research Institute, Minho University Medical School

  • Rui Manuel Fonseca Pinto, MD, PhD · ciTechCare - Center for Innovative Care and Health Technology, Polytechnic University of Leiria

  • João Carlos Araújo Morais, MD,PhD · ciTechCare - Center for Innovative Care and Health Technology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-02
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • Portugal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07288840 on ClinicalTrials.gov